WallStreetZenWallStreetZen

NASDAQ: PLRX
Pliant Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PLRX

Based on 6 analysts offering 12 month price targets for Pliant Therapeutics Inc

Min Forecast
$1.50+2.74%
Avg Forecast
$3.92+168.29%
Max Forecast
$10.00+584.93%

Should I buy or sell PLRX stock?

Based on 6 analysts offering ratings for Pliant Therapeutics Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
6 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although PLRX's forecast from analysts indicates a "Hold", our proven Zen Rating quant model rates PLRX as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their PLRX stock forecasts and price targets.

PLRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-04
lockedlocked$00.00+00.00%2025-03-04
lockedlocked$00.00+00.00%2025-03-04
lockedlocked$00.00+00.00%2025-03-04
lockedlocked$00.00+00.00%2025-03-03
Canaccord Genuity
Top 10%
91
HoldDowngrades$4.00+173.97%2025-02-10

1 of 1

Forecast return on equity

Is PLRX forecast to generate an efficient return?

Company
26.92%
Industry
118.54%
Market
79.49%
PLRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PLRX forecast to generate an efficient return on assets?

Company
20.62%
Industry
38.01%
PLRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PLRX earnings per share forecast

What is PLRX's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$2.72
Avg 2 year Forecast
-$2.69
Avg 3 year Forecast
-$1.80

PLRX revenue forecast

What is PLRX's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$119.5M
Avg 2 year Forecast
$321.4M
Avg 3 year Forecast
$729.0M

PLRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PLRX$1.46$3.92+168.29%Hold
ELTX$5.57$10.00+79.53%Buy
NAUT$0.72$1.75+144.76%Strong Sell
GALT$1.40$11.00+685.71%Buy
ZNTL$1.26$6.04+379.37%Buy
View Top Biotech Stocks

Pliant Therapeutics Stock Forecast FAQ

Is Pliant Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: PLRX) stock is to Hold PLRX stock.

Out of 6 analysts, 0 (0%) are recommending PLRX as a Strong Buy, 0 (0%) are recommending PLRX as a Buy, 6 (100%) are recommending PLRX as a Hold, 0 (0%) are recommending PLRX as a Sell, and 0 (0%) are recommending PLRX as a Strong Sell.

If you're new to stock investing, here's how to buy Pliant Therapeutics stock.

What is PLRX's earnings growth forecast for 2025-2027?

(NASDAQ: PLRX) Pliant Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.83%.

Pliant Therapeutics's earnings in 2025 is -$210,304,000.On average, 8 Wall Street analysts forecast PLRX's earnings for 2025 to be -$166,256,530, with the lowest PLRX earnings forecast at -$320,265,802, and the highest PLRX earnings forecast at -$89,404,985. On average, 7 Wall Street analysts forecast PLRX's earnings for 2026 to be -$164,639,892, with the lowest PLRX earnings forecast at -$406,608,972, and the highest PLRX earnings forecast at -$35,517,049.

In 2027, PLRX is forecast to generate -$110,072,233 in earnings, with the lowest earnings forecast at -$232,085,543 and the highest earnings forecast at -$19,595,613.

What is PLRX's revenue growth forecast for 2027-2029?

(NASDAQ: PLRX) Pliant Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.66%.

Pliant Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast PLRX's revenue for 2027 to be $7,319,880,045, with the lowest PLRX revenue forecast at $2,987,718,638, and the highest PLRX revenue forecast at $11,652,041,451. On average, 3 Wall Street analysts forecast PLRX's revenue for 2028 to be $19,680,915,273, with the lowest PLRX revenue forecast at $7,898,256,813, and the highest PLRX revenue forecast at $42,777,835,804.

In 2029, PLRX is forecast to generate $44,641,256,139 in revenue, with the lowest revenue forecast at $15,574,225,890 and the highest revenue forecast at $81,130,124,857.

What is PLRX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: PLRX) forecast ROA is 20.62%, which is lower than the forecast US Biotechnology industry average of 38.01%.

What is PLRX's Price Target?

According to 6 Wall Street analysts that have issued a 1 year PLRX price target, the average PLRX price target is $3.92, with the highest PLRX stock price forecast at $10.00 and the lowest PLRX stock price forecast at $1.50.

On average, Wall Street analysts predict that Pliant Therapeutics's share price could reach $3.92 by Mar 4, 2026. The average Pliant Therapeutics stock price prediction forecasts a potential upside of 168.29% from the current PLRX share price of $1.46.

What is PLRX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: PLRX) Pliant Therapeutics's current Earnings Per Share (EPS) is -$3.47. On average, analysts forecast that PLRX's EPS will be -$2.72 for 2025, with the lowest EPS forecast at -$5.23, and the highest EPS forecast at -$1.46. On average, analysts forecast that PLRX's EPS will be -$2.69 for 2026, with the lowest EPS forecast at -$6.64, and the highest EPS forecast at -$0.58. In 2027, PLRX's EPS is forecast to hit -$1.80 (min: -$3.79, max: -$0.32).

What is PLRX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: PLRX) forecast ROE is 26.92%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.